Pentoxifylline treatment in severe acute pancreatitis: A pilot, double-blind, placebo-controlled, randomized trial

Santhi Swaroop Vege, Tegpal Atwal, Yan Bi, Suresh T Chari, Magdalen A. Clemens, Felicity T Enders

Research output: Contribution to journalArticle

15 Scopus citations


In acute pancreatitis (AP) tumor necrosis factor-α mediates multi-organ failure; in animal models its blockade with pentoxifylline ameliorates AP. The efficacy of pentoxifylline in predicted severe AP (pSAP) was tested in a double-blinded, randomized, control trial. Twenty-eight patients with pSAP were randomized within 72 hours of diagnosis to pentoxifylline or placebo. Baseline characteristics were similar in both groups. The pentoxifylline group had fewer intensive care unit admissions and shorter intensive care unit and hospital stays of longer than 4 days (all P <.05). Patients receiving pentoxifylline had no adverse effects. Pentoxifylline within 72 hours of pSAP is safe; a larger study of pentoxifylline in AP is needed to confirm efficacy.

Original languageEnglish (US)
Pages (from-to)318-320.e3
Issue number2
StatePublished - Aug 1 2015



  • IL6
  • IL8
  • Pentoxifylline
  • Tumor Necrosis Factor-α

ASJC Scopus subject areas

  • Gastroenterology

Cite this